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Studies, and Network Meta-AnalysesComparative effectiveness research incorporates study designs
extending beyond the randomized controlled trial (RCT) [1], which
is the touchstone for demonstrating therapeutic efﬁcacy. The
litany of RCT ﬂaws is often recited: not real world, not real
patients, not real settings, not available, not timely, and not
affordable. Although not every RCT is well designed, there are
established narratives and tools to aid health care decision makers
in appraising and interpreting them. The Comparative Effective-
ness Research Collaborative Initiative is a collective effort among
the Academy of Managed Care Pharmacy, the National Pharma-
ceutical Council, and the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) to provide tools for
decision makers to assess studies that use nonexperimental
methods important to comparative effectiveness research. To this
end, ISPOR Good Practices Task Forces have developed tools to
assess 1) prospective and retrospective observational studies, 2)
modeling studies, and 3) network meta-analysis studies.Questionnaires to Assess the Relevance and
Credibility of a Study
The tools are straightforward in design and purpose. Each Task Force
developed a questionnaire to assess the relevance and credibility of
its assigned study design. The Task Forces wisely rejected linking the
questionnaires to scorecards or checklists. Scoring systems encou-
rage a false sense of precision [2]. Checklists tempt the user into
“vote-counting,” creating an implicit score. The purpose of the
questionnaire is to guide the user to formulate an understanding
of the strengths and weaknesses of each study reviewed.
The ﬁrst-order consideration is whether a study is relevant to
the issue at hand. The three questionnaires use common rele-
vance criteria, derivative of the well-known patient population,
interventions, comparators, outcomes, and settings (PICOTS)
framework. The relevance criteria address population, interven-
tions, outcomes, and context (settings and circumstances). Nota-
bly, the criteria ask whether important interventions and out-
comes are missing. What is not reported is as important, and
often more so, than what is reported. Selective reporting, focus
on intermediate or short-term outcomes, bias in the comparator
interventions, sparse attention to adverse effects—all are notor-
ious threats to the evidence base for decision making [3].
If relevant, is the study credible? Domains to assess study
credibility are speciﬁc to each study design. Credibility goes to the
heart of the design, conduct, and reporting of a study. Are the
results dependable for decision making? Are the results action-
able? Of course, a single study is rarely deﬁnitive. Theial support: The authors have no other ﬁnancial rquestionnaires presented here address individual studies, not
the credibility of a body of evidence on an issue. The Comparative
Effectiveness Research Collaborative Initiative has addressed
appraisal and synthesis of a body of evidence elsewhere.
Assessing the credibility of observational and modeling stu-
dies as well as network meta-analyses can challenge even a
familiar reader. The many questions concerning the credibility of
observational studies no doubt reﬂect the difﬁculties in assessing
causal treatment effects outside an RCT [4]. The questionnaire
provides a guide through many of these difﬁculties; unfortu-
nately, the implications for decision makers may not be as clear
as one would like. Assessing the credibility of a modeling study
follows a more linear and straightforward path. It is reﬂected in
the questionnaire organization. Conceptually integrating the
various domains is also somewhat intuitive. Last, network
meta-analyses can be complex undertakings and understanding
the credibility of results and conclusions complex as well. The
questionnaire manages to skillfully highlight the important
domains and offers considerable clarity. The arguably necessary
detail is substantial and some notions may be difﬁcult, but the
document should provide the underpinnings needed by a stu-
dious decision maker to evaluate credibility.
Conﬂict of interest is a credibility domain in all three ques-
tionnaires. Questions for the conﬂict of interest domain are as
follows: (a) Were there any potential conﬂicts of interest? and (b)
If there were potential conﬂicts of interest, were steps taken to
address these? Of concern, the three questionnaires differ in the
guidance provided on how to apply the questions. The observa-
tional studies questionnaire is most informative on the ﬁrst
question. Users are advised to search public sources because
the lack of disclosure of conﬂict should not be construed as
absence of conﬂict. As to steps to address conﬂicts, the ques-
tionnaires do offer minimal advice; the modeling studies report is
silent on the matter. Admittedly, how to address conﬂict of
interest is a thorny issue [5]. ISPOR could provide leadership by
creating a good practice Task Force on this topic.Utility of the Questionnaires
Each Task Force conducted user testing, calculating multirater
agreement for the credibility domain. Multirater agreement was
less than 60% for the observational studies questionnaire, and
ratings were not provided 15% to 36% of the time. The network
meta-analysis questionnaire had an average agreement score of
72%, with a range of 42% to 91%. Network meta-analysis is a new
method, and familiarity with this method is likely limited amongelationships to disclose.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 4 1 – 1 4 2142decision makers. The higher rate of agreement than reported for
the more familiar observational studies suggests that the respon-
dents were a group likely conversant with network analysis.
There was insufﬁcient response to user testing of the modeling
tool to report the results.
Decision makers (and their organizations) vary in their capacity
to conduct appraisal of study methodology. The Task Force reports
endorse education of users and provide a Web-based training tool
to aid users and promote uptake. An alternative, and also com-
plementary, approach is to create a curated online inventory of
completed questionnaires. Many users will be interested in similar
questions and assessing the same articles. Experienced curators
could review the questionnaires submitted, providing commentary
and a learning resource to improve users’ facility with the ques-
tionnaire. Some decision makers will ﬁnd it more efﬁcient to simply
consult the repository than to conduct their own review. The
inventory could also be indexed by the relevance criteria, so that
decision makers would have access to a collection of reviewed
articles relevant to the topic of interest.
Although such an online repository would require an invest-
ment of resources from ISPOR, the beneﬁt to users would be
substantial. The Agency for Healthcare Research and Quality has
undertaken such a repository for systematic review data abstrac-
tion. The repository would pool effort and access to a collection of
articles and topics larger than can be accomplished by any one
organization alone. It is important for multiple reviewers to assess
an article. But there is also a point of diminishing returns, and so
further effort is an exercise in redundancy, not reproducibility.Naomi Aronson, PhD,
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